Nephro Care India Board of Directors

Get the latest insights into the leadership at Nephro Care India. Learn about the experienced professionals guiding the company's strategy and governance.

NamePosition
Dr. Pratim Sengupta Managing Director
Dr. Pritam Sengupta Non Exe.Non Ind.Director
Mr. Alo Sengupta Independent Director
Mr. Saikat Biswas Independent Director
Mr. Sudip Barman Independent Director
Ms. Sutapa Sen Non Exe.Non Ind.Director

Nephro Care India Share price

NEPHROCARE

169

0.00 (0.00%)
NSE
BSE
Last updated on 4 Sep, 2025 | 15:24 IST
BUYSELL
Today's High

173.95

Today's Low

162.00

52 Week Low

99.95

52 Week High

289.00

The current prices are delayed, login to your account for live prices

Nephro Care India FAQs

The board at Nephro Care India consists of experienced professionals, including Dr. Pratim Sengupta , Dr. Pritam Sengupta , and others, overseeing the company’s strategic and corporate governance.

Directors at Nephro Care India are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.

As of the latest update, Dr. Pratim Sengupta is the current chairman at Nephro Care India.

Executive directors at Nephro Care India are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.

Yes, Nephro Care India adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.

At Nephro Care India, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.